BALAXI PHARMACEUTICALS LIMITED (BALAXI) — Board Meeting | 24 August 2026

· NSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
83rd AGM approved financial statements and director reappointments
💡 Investor Takeaway
Shareholders endorsed financial results and leadership continuity, signaling stability but no immediate growth catalyst.

BALAXI PHARMACEUTICALS LIMITED held its 83rd Annual General Meeting on 24 August 2026 via video conference, where shareholders approved the adoption of standalone and consolidated audited financial statements, re-appointed Mrs. Minoshi Maheshwari as Director, and re-appointed Ms. Akshita Ostwal as Independent Director. Chairman Ashish Maheshwari addressed queries, and the meeting concluded at 11:55 AM IST after 15 minutes of post-AGM e-voting.

📄 View Original Announcement (PDF)

About BALAXI PHARMACEUTICALS LIMITED (BALAXI)

Healthcare · Pharmaceuticals · Listed on NSE

ROE: 1.1% ROCE: 3.6%

View full BALAXI stock details →

📡 Get AI alerts when BALAXI files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track BALAXI — Free

📊 More BALAXI filings

See all BALAXI filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when BALAXI files new disclosures

Track BALAXI filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track BALAXI — Free

Free account · 2 AI queries/day